Platelet-rich plasma injections for the treatment of knee osteoarthritis: a prospective clinical study

This article was originally published here

J Clin Med. 2022 May 8;11(9):2640. doi: 10.3390/jcm11092640.


BACKGROUND: The aim of this prospective study was to evaluate the efficacy and safety of platelet-rich plasma (PRP) injections in patients with knee osteoarthritis (KOA). An autologous blood product containing a high percentage of various growth factors (GF), cytokines and modulating factors like PRP has shown promising results in achieving this goal.

METHODS: One hundred fifty-three patients (72 men, mean age 59.06 ± 8.78, age range 40-81 years) from January 2018 to January 2020 received three consecutive PRP injections and completed follow-ups. Western Ontario and McMaster University Osteoarthritis Index (WOMAC), Knee Society Score (KSS), and Visual Analog Scale (VAS) were assessed before PRP injection (T0) , one month (T1), three months (T2) and six months (T3) after treatment. All patients underwent an initial assessment and at 6 months an MRI and X-ray.

RESULTS: A statistically significant reduction in VAS, KSS, and WOMAC appeared in the comparison between assessments (p p = 0.46 and p = 0.33 respectively), and no radiographic changes could be observed in any patient.

CONCLUSIONS: PRP injection represents a valid conservative treatment to reduce pain, improve quality of life and functional scores even at the midpoint of 6-month follow-up.

PMID:35566766 | DO I:10.3390/jcm11092640